高级检索
当前位置: 首页 > 详情页

Expression and Clinical Significance of Microtubule-Actin Cross-Linking Factor 1 in Serous Ovarian Cancer.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 13 Shiliugang ST, Guangzhou 510315. China. [2]Department of Gynecology, Guangdong Women and Children Hospital, Guangzhou 511442. China. [3]Department of Gynecology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 13 Shiliugang ST, Guangzhou 510315. China. [4]Department of Obstetrics and Gynecology, Third Affiliated Hospital, Southern Medical University, Guangzhou 510630. China. [5]Department of Gynecology Oncology, the Memorial hospital of Sun Yat-sen University, 510000. China.
出处:
ISSN:

摘要:
Ovarian cancer (OC) remains the first leading cause of gynecologic malignancy. The survival of Serous Ovarian Cancer (SOC) is poor and the present prognostic predictors of SOC are not very sensitive or specific. The present study aimed to investigate Microtubule-Actin Cross-Linking Factor 1 (MACF1) expression in SOC tissues (including paraffin-embedded and fresh tissues) and to assess its expression and significant value in patients with SOC. A total of 18 fresh SOC tissues and their paired paratumor tissues were performed with reverse-transcription quantitative PCR analysis to detect MACF1 mRNA expression. Moreover, 175 paraffin embedded SOC tissues and 41 paratumor tissues were assessed for MACF1 expression using immunohistochemistry. The mRNA and protein expression of MACF1 were both higher in cancer tissues than that in paratumor tissues, and MACF1 high expression was associated with shorter Recurrence Free Survival (RFS) and Overall Survival (OS) in patients with SOC. Furthermore, multivariate regression analysis showed that high MACF1 expression was an independent poor survival predictor of patients with SOC. MACF1 is upregualted in SOC, and it may be used as a useful patent of prognostic biomarker in SOC. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 药学
最新[2025]版
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 药学
JCR分区:
出版当年[2019]版:
Q3 PHARMACOLOGY & PHARMACY Q3 ONCOLOGY
最新[2023]版:
Q3 ONCOLOGY Q3 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 13 Shiliugang ST, Guangzhou 510315. China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2022 今日访问量:0 总访问量:648 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号